Given the urgent need to improve the PDAC patient response to immunotherapies and the critical role of pSer784-VCP in DDR, future studies are warranted to also investigate the impact of pSer784-VCP on tumor microenvironment and its clinical implication for cancer immunotherapies. This evidence concerns the gene VCP and neoplasm.